Rometty Lisa Ann 4

4 · Rani Therapeutics Holdings, Inc. · Filed Dec 19, 2023

Form 4

Period: 2023-12-16

Director

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2023-12-16−101,276→ 0 total
Exercise: $4.11Exp: 2033-05-24→ Class A Common Stock (101,276 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-12-16−17,708→ 31,329 total
Exercise: $17.00Exp: 2032-01-02→ Class A Common Stock (17,708 underlying)
Award
Stock Option (Right to Buy)
2023-12-16+101,276→ 101,276 total
Exercise: $2.84Exp: 2033-05-24→ Class A Common Stock (101,276 underlying)
Award
Stock Option (Right to Buy)
2023-12-16+17,708→ 17,708 total
Exercise: $2.84Exp: 2032-01-02→ Class A Common Stock (17,708 underlying)

Footnotes (4)

[F1]The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan).
[F2]The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options.
[F3]The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date.
[F4]The shares subject to the option vest as follows: 1/3rd of the shares subject to the option vest on January 3, 2023; and 1/36th of the shares subject to the option vest monthly over the following two years.

Documents

1 file